{"name":"Castle Biosciences","slug":"castle-bio","ticker":"CSTL","exchange":"NASDAQ","domain":"castlebiosciences.com","description":"Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE; AdvanceAD-Tx, a non-invasive GEP test which is designed to guide systemic treatment selection for patients aged 12 years and older with moderateto-severe AD; DecisionDx-SCC, a GEP test for cutaneous squamous cell carcinoma; and MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions. It al","hq":"Friendswood, TX","founded":0,"employees":"883","ceo":"Derek Maetzold","sector":"Diagnostics / Precision Medicine","stockPrice":25.41,"stockChange":0.58,"stockChangePercent":2.34,"marketCap":"$756M","metrics":{"revenue":344229000,"revenueGrowth":0.8,"grossMargin":79.4,"rdSpend":51850000,"netIncome":-24158000,"cash":299504992,"dividendYield":0,"peRatio":-46.7,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-22","type":"earnings","headline":"Castle Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Castle Biosciences reported fourth quarter and full year 2023 financial results, with revenue increasing 24% year-over-year to $143.1 million.","drugName":"","sentiment":"positive"},{"date":"2023-11-15","type":"deal","headline":"Castle Biosciences Announces Collaboration with National Cancer Institute","summary":"Castle Biosciences announced a collaboration with the National Cancer Institute to develop and commercialize a new diagnostic test for skin cancer.","drugName":"","sentiment":"positive"},{"date":"2023-08-17","type":"regulatory","headline":"Castle Biosciences Receives FDA Clearance for DecisionDx-Melanoma Test","summary":"Castle Biosciences received FDA clearance for its DecisionDx-Melanoma test, a diagnostic test for melanoma.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxPbUhrMEt2MGJDaElKdEwtSElVVUVKdFF4RU9VMGU3VkRlR1hPazlfaXh2aDJoMUJSRTRXV2Y5aHoxLUhSY1FsTk5IRER6Uk91OV9fbFRBQ3JJY0Rwdy1USTdtd0U5ZkdOWUlGdUx2THlvNWdSd0VTY3lyS2h1TXY3MnBDekhRSWpsZ3VXV0dzbGlRQzI0d3o0XzBn?oc=5","date":"2026-03-02","type":"pipeline","source":"Finviz","summary":"LLY Wins CHMP Nod for Olumiant's Expanded Use in Alopecia Areata - Finviz","headline":"LLY Wins CHMP Nod for Olumiant's Expanded Use in Alopecia Areata","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxQdldsellnNVdxcnV3WHhTUVNidzZBZ3dBVGlwWTZzdWs3djVvbkEyMVJaNC1ydDBKazFHdHg3cEpwS0wyVkJBajZrdVJiTkhFOFQwd0lESzV3dEZrYTdSdUVSbTZBcERMbm5NLTl4MkNYTkhiWHZPbGdvY2l4b1hIREpUbTNjeUpnWFhlUFRjbE1VQXVOMjRNa3NNTEpvYXpTVWtraG9qdzlhal9TZmsxVWFB?oc=5","date":"2026-02-27","type":"earnings","source":"TradingView","summary":"RCKT's Q4 Loss Narrower Than Estimated, Pipeline in Focus - TradingView","headline":"RCKT's Q4 Loss Narrower Than Estimated, Pipeline in Focus","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxPQ0ExclBkRW5FM25Kcmt3YUhleFhQQ2gtYVVJSEE0UHNhYWlvRTF4eUd1Qy01M3ZGbnVHV1NXQU43akR5TGdQMWZ1cGRzSGQ1eUdKSGlNT2Zwd0NxTmpsd0tTeXhiUG5GWWIzQWxLNlNnOWdJZ1B3XzhhaTIzaVcyc0NTVkI5d2laYUNLSlZrNF85bHRNTjdfN0dCUDB0LTQ?oc=5","date":"2026-02-26","type":"earnings","source":"Finviz","summary":"Catalyst Pharmaceuticals Q4 Earnings Beat, Firdapse Revenues Rise Y/Y - Finviz","headline":"Catalyst Pharmaceuticals Q4 Earnings Beat, Firdapse Revenues Rise Y/Y","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxNMlVMWlBQTmZ4SzQ4TnNIQnVQQjI2QmJXblNuWnZxVndTekhGR0xWc2VaWFFoRFNhbm5MdTluTGFHcWFlUUxWMGdnS01TMmdfWW50SkNVUkcyNGZJcTZ0M2NPbkVUWWdkRjZWOXFWcy1lMnpUdUpPVDZKbkw3MVNrQllxaDg2cjRQM0N0NjFpM0d0YXMwQ1E0?oc=5","date":"2026-02-26","type":"earnings","source":"Finviz","summary":"Mirum's Q4 Earnings Lag, Higher Product Sales Drive Y/Y Revenues - Finviz","headline":"Mirum's Q4 Earnings Lag, Higher Product Sales Drive Y/Y Revenues","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxNQ1BhbVhHOVlBaVprcmtTb2dRUFZ2NXBDTXRCbVc1aDE2ZlVhemhXdGlzWVd6T3kzR1FCV1RkOUxOVm9hVkpIVnR6eENCWTF6ZzZSdG1BWGV0cVhtNjNkb2VrdE9zeG92WU4yNzVqUzYzMTZaaFVJcGJ2SmI3cHg0ZG9zWHA4SjdMbC1WbUV2ZExlZW55eHkxUlNoVmtMMG1ncFhEb3FoanVNQnlGcXViYXY5T1VNTUJjdU5zVzRYanhyMHhiVGh4TjJYaWxXNnh4R3dIOA?oc=5","date":"2026-02-26","type":"earnings","source":"Eastern Progress","summary":"Viatris Q4 EPS Tops, Brands Drive Revenue Growth, Stock Up - Eastern Progress","headline":"Viatris Q4 EPS Tops, Brands Drive Revenue Growth, Stock Up","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxNVXZpNjVSY281NWpFWUdxVVp5OHFwZlhJVFJkLW95X1UwMHROYl9BMUVseUJfaG5TVUt4U2VBU2NOb2NoQnpYeGJnemlLR0pJS0wyWVh2dnhkYXo4bUlsZ2FlYmFwTGhFanpXQ0h4ZEtEak5TSjZYdDVWQmoxS2lGVTlKUWVBY0ZNd204TUR3?oc=5","date":"2026-02-25","type":"earnings","source":"Finviz","summary":"JAZZ Stock Rises as Q4 Earnings & Sales Top Expectations - Finviz","headline":"JAZZ Stock Rises as Q4 Earnings & Sales Top Expectations","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxOSmtmT1Q4eW82WWVMbUVqVTl0Wkdfa09BaEpqaHNob0JTZHAwWTZGTy0xdlJOTVF1bnFIdE1CaDdTTFBCV2JHa1VPQ0hHVU5JYTJNblF5T1hGWk9qVUxxdXZGTFZHMHdUcklqX3BNNVd4ZlBiUldUSDV5dndoRVhjNjhwVmEzUVVkRWRuV1FCMTd4VFBhOWxGbDV3WEtSVHNpc01mMGN6NVNwTTloYm9zaQ?oc=5","date":"2026-02-23","type":"earnings","source":"TradingView","summary":"Viatris Stock to Report Q4 Earnings: What's in the Cards? - TradingView","headline":"Viatris Stock to Report Q4 Earnings: What's in the Cards?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxQNW5Ka2NicjBvXzFSZWd1dEJWZWh1eVNMaUN2SHpRUEp3OE1uaDBOQXMybi1CamR6VmN5aHpyeXBLRzlDOEFyZ3lhWXo5Y2pNSUN2VXBydkxlQ1ZIeV8tcEZObmtiZ21Jc2d0WU9WWGN5V1NRWW52QUZMcklTYUhrXzY3X1pQU05vSnI3YlFRbGg2d0NPcmRLMWJra0Z4Y2c?oc=5","date":"2026-02-20","type":"earnings","source":"Finviz","summary":"Madrigal Q4 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Down - Finviz","headline":"Madrigal Q4 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Down","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxQRDVhT0JnbktwYTVHS3Yxb3BOLTRkd2Z4TmRyT3h1RW1EWTlCd2dVSkJCSHlmMlctQ0gtdTBKYW5MWTl6Nm5mLUZndmlqOGNkaWN5NzlZMHVxN2lVRHp4RGpPbURUQzhoTUhwbWE0R1NGT0N5UWdEVUQ0MlMwbFJsWmREQnljM2R2NGo4Q1ppcldobXdKOVBKQ1BlbGFvQmRMamd5SkhFLWNiT0M0dHpIZV9EUGhXOW9ZR1VZWXpwWDljZjVNMXVJa2pZRlRWT01VenlXY1E3NUJGTzVLWFpQMQ?oc=5","date":"2026-02-19","type":"earnings","source":"Eastern Progress","summary":"Collegium Pharmaceutical to Report Q4 Earnings: What's in the Cards? - Eastern Progress","headline":"Collegium Pharmaceutical to Report Q4 Earnings: What's in the Cards?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxQeGNEVUpaMWFhMG9jYy01QWFQejVkRkxNa0Z0Z182QVhfWmFuVmZLcTdnbmZvQWZkVGdrbUltZENxRWtKX0o2R19YdVZkOWkzQXlLbXZpU2NCQUtyWjdGQTZvdmw1aDZRSDVDQTlZN183dVBnWEpFaXRYb01qUmlacV9ya0R0NW5wUUgySUVFRkRDUS1oSnpUNUlGSlMyS09JVDhPaWtRUlhFZGw0bVNWeGZMcElyeWNyUTNEMTNaRXI?oc=5","date":"2026-02-17","type":"earnings","source":"TradingView","summary":"Recursion Pharmaceuticals to Report Q4 Earnings: What's in the Cards? - TradingView","headline":"Recursion Pharmaceuticals to Report Q4 Earnings: What's in the Cards?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxQUWVvdWttNnBQR0JCVjZ3eE9icGVkNlR3bTB0c0VfbVV4azNXUWc1VFAwYUtyMlFKa01ZdGhySzRnTWpFTXRhQmUxV1BDQjhmMjJNUS11aFdxQXBpSFA0Y240R0FNNEN0cXlXWFlkVHVlRXBYbUxqZkJURERlTWVvbDdIdEc4WXZpVWc1ekNkQnl6bUxvMnF6dWRmX1BvcUxFM29zLXBSR3lzS0pva0h2MDZtWlZBUQ?oc=5","date":"2026-02-13","type":"earnings","source":"TradingView","summary":"Agios Pharmaceuticals Incurs Narrower-Than-Expected Q4 Loss - TradingView","headline":"Agios Pharmaceuticals Incurs Narrower-Than-Expected Q4 Loss","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxQbWRROEpIdnpaUWlxMnRoZS1WV2swaEtVS3hwVjQzRHZXa3VPbVZmNk1GOE1WN2lzdUFnYWRqX1JWdzVBYVJMN1QwRTF5VEFlYU5ZakNxcFlEQzVZcEhVTUtCVGtxdDJLRlFXMy1vN010ZEVqMVloQWprdkFxdW81SmxJdTBHU1BJS2FWMF9yR2tTWkFmbGZKci02UzRwY1Zid0hhMDRvYTNLeWZXS1pScXFlalB4Q0E?oc=5","date":"2026-02-13","type":"earnings","source":"TradingView","summary":"Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y - TradingView","headline":"Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Exact Sciences","Invitae","Foundation Medicine"],"therapeuticFocus":["Skin Cancer","Precision Medicine"],"financials":{"source":"sec_edgar","revenue":344229000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":344229000,"period":"2025-12-31"},{"value":332069000,"period":"2024-12-31"},{"value":332069000,"period":"2024-12-31"},{"value":219788000,"period":"2023-12-31"},{"value":219788000,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":51850000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-24158000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":578556000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":25.41,"previousClose":24.83,"fiftyTwoWeekHigh":44.28,"fiftyTwoWeekLow":14.59,"fiftyTwoWeekRange":"14.59 - 44.28","fiftyDayAverage":30.2,"twoHundredDayAverage":27.96,"beta":1.19,"enterpriseValue":475735648,"forwardPE":-46.7,"priceToBook":1.6,"priceToSales":2.2,"enterpriseToRevenue":1.38,"enterpriseToEbitda":-233.32,"pegRatio":0,"ebitda":-2039000,"ebitdaMargin":-0.6,"freeCashflow":41212500,"operatingCashflow":64347000,"totalDebt":37015000,"debtToEquity":7.9,"currentRatio":5.26,"returnOnAssets":-2.6,"returnOnEquity":-5.2,"analystRating":"1.0 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":8,"targetMeanPrice":48.5,"targetHighPrice":52,"targetLowPrice":44,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":2.6,"institutionHeldPercent":93.2,"sharesOutstanding":29731198,"floatShares":25169540,"sharesShort":1429011,"shortRatio":3.32,"shortPercentOfFloat":4.8,"epsTrailing":-0.83,"epsForward":-0.54,"revenuePerShare":11.88,"bookValue":15.86,"officers":[{"age":63,"name":"Mr. Derek J. Maetzold","title":"Founder, CEO, President & Director"},{"age":54,"name":"Mr. Frank  Stokes","title":"CFO & Treasurer"},{"age":57,"name":"Ms. Kristen M. Oelschlager R.N.","title":"Chief Operating Officer"},{"age":64,"name":"Mr. Tobin W. Juvenal","title":"Chief Commercial Officer"},{"age":null,"name":"Ms. Camilla  Zuckero","title":"Vice President of Investor Relations & Corporate Affairs"},{"age":null,"name":"Mr. Kevin  Doman","title":"Vice President of Sales"},{"age":null,"name":"Dr. Jay  Braxton Pharm.D.","title":"VP of Marketing & Brand Manager of Uveal Melanoma (UM)"},{"age":null,"name":"Ms. Keli  Greenberg","title":"Vice President of Human Resources"}],"industry":"Diagnostics & Research","irWebsite":"","website":"https://castlebiosciences.com","phone":"866 788 9007"}}